Article
Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial.
BMC medicine - 1 Feb 2022
Song Zhengbo, Li Yuping, Chen Shiqing, Ying Shenpeng, Xu Shuguang, Huang Jianjin, Wu Dan, Lv Dongqing, Bei Ting, Liu Shuxun, Huang Xiaoping, Xie Congying, Wu Xiaoyu, Fu Jianfei, Hua Feng, Wang Wenxian, Xu Chunwei, Gao Chan, Cai Shangli, Lu Shun, Zhang Yiping
Abstract excerpt
BACKGROUND: There is currently a lack of effective treatments for non-small cell lung cancer (NSCLC) patients harboring HER2 mutations. We examined the efficacy and safety of, and potential resistance mechanism to, pyrotinib, a pan-HER inhibitor, in advanced NSCLC carrying HER2 mutations. METHODS: In this multicenter, single-arm, phase II trial, stage IIIB-IV NSCLC patients harboring HER2 mutations, as determined...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.